Ligand Pharmaceuticals Incorporated

Welcome to Ligand Pharmaceuticals

Ligand is a high-growth company with economic rights to some of the world's most important medicines.

Ligand Fourth Quarter 2022 Earnings Webcast

Portfolio

Portfolio

Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.

Learn More
Technologies

Technologies

Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.

Learn More
Licensing Opportunities

Licensing Opportunities

Ligand has multiple technologies and unpartnered programs available for out-licensing.

Learn More

Investor Relations

View Investor Relations Latest Corporate Presentation

Latest News

Ligand Reports Fourth Quarter and Full Year 2022 Financial Results

Read More

Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy

Read More

Ligand to Report Fourth Quarter Financial Results on February 22

Read More

Recent Events

Stock Snapshot

LGND
Nasdaq
Volume
Market Cap
Day Range
52-Week Range